cagrilintide semaglutide New in the August 14, 2025, issue of NEJM: Cagrilintide–Semaglutide for Overweight or Obesity (REDEFINE 1 phase 3a trial) Cagrilintide– for Overweight and Diabetes (REDEFINE 2 phase 3a trial) Semaglutide + Cagrilintide Blend (Research)
Description
This includes displaying broadly neutralizing L2 epitopes on bacteriophage platforms (e.g., PP7 VLPs) (Tumban et al., 2011, 2015) or utilizing thioredoxin-based multiepitope nanoparticles (Spagnoli et al., 2017)
This also connects to how BPC-157 handles pain
According to Health Canada, though injectable peptides are regulated as prescription drugs, the department has not authorized any of the products that were seized or sold on the companys website
2012 May;47(1):144-9
But the FDA has previously warned that they pose safety risks and barred pharmacies from compounding many of them
What is your protocol if I have an adverse reaction
